Comparing Intubating Conditions Using Succinylcholine or Rocuronium for Rigid Bronchoscopy
Information source: Dr. Horst Schmidt Klinik GmbH
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Intubating Conditions; Postoperative Myalgia; Patient Satisfaction
Intervention: Succinylcholine (Drug); Rocuronium 0,3 (Drug); Rocuronium 0,6 (Drug)
Phase: N/A
Status: Not yet recruiting
Sponsored by: Dr. Horst Schmidt Klinik GmbH Official(s) and/or principal investigator(s):
Grietje Beck, Prof, Study Chair, Affiliation: Dr. Horst Schmidt Klinik
Overall contact:
Grietje Beck, Prof, Phone: 0049 611 432176, Email: grietje.beck@hsk-wiesbaden.de
Summary
Succinylcholine is commonly used for neuromuscular relaxation for short procedures such as
rigid bronchoscopy. A more modern alternative is the application aof rocuronium, reversed by
sugammadex. The investigators compare the intubating conditions, incidence of postoperative
myalgia (POM) as well as patient satisfaction for these two muscle relaxants.
Clinical Details
Official title: Comparing Intubating Conditions Using Succinylcholine or Rocuronium/Sugammadex for Rigid Bronchoscopy: a Randomized Study
Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Primary outcome: Intubating Condition
Secondary outcome: Postoperative Myalgia
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- age > 18 yr
- scheduled for elective rigid bronchoscopy
Exclusion Criteria:
- known neuromuscular disease
- significant hepatic or renal dysfunction
- family history of malignant hyperthermia
- known allergy to one of the drugs used in this protocol
- pregnancy or breastfeeding
Locations and Contacts
Grietje Beck, Prof, Phone: 0049 611 432176, Email: grietje.beck@hsk-wiesbaden.de
Dr. Horst Schmidt Klinik, Wiesbaden, Hessen 65199, Germany; Not yet recruiting
Grietje Beck, Prof, Phone: 0049 611 432176
Verena Ghezel-Ahmadi, Dr, Principal Investigator
Additional Information
Starting date: August 2015
Last updated: March 23, 2015
|
